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Abstract
Background: In the Netherlands, absenteeism and reduced productivity due to work disability lead to high yearly
costs reaching almost 5% of the gross national product. To reduce the economic burden of sick leave and reduced
productivity, different employability interventions for work-disabled employees or employees at risk of work
disability have been developed. Within this study, called ‘CASE-study’ (Cost-effectiveness Analysis of Sustainable
Employability), five different employability interventions directed at work disabled employees with divergent health
complaints will be analysed on their effectiveness and cost-effectiveness. This paper describes a consistent and
transparent methodological design to do so.
Methods/design: Per employability intervention 142 participants are needed whereof approximately 66
participants receiving the intervention will be compared with 66 participants receiving usual care. Based on the
intervention-specific characteristics, a randomized control trial or a quasi-experiment with match-criteria will be
conducted. Notwithstanding the study design, eligible participants will be employees aged 18 to 63, working at
least 12 h per week, and at risk of work disability, or already work-disabled due to medical restrictions. The primary
outcome will be the duration of sick leave. Secondary outcomes are health status and quality of life. Outcomes will
be assessed at baseline and then 6, 12 and 18 months later. Economic costs will consist of healthcare costs and
cost of lost production due to work disability, and will be evaluated from a societal perspective.
Discussion: The CASE-study is the first to conduct economic evaluations of multiple different employability
interventions based on a similar methodological framework. The cost-effectiveness results for every employability
intervention will be published in 2014, but the methods, strengths and weaknesses of the study protocol are
discussed in this paper. To contribute to treatment options in occupational health practice and enable the
development of guidelines on how to conduct economic evaluation better suited to this field; this paper provides
an important first step.
Trial registration: Four trials involved in the CASE-study are registered with the Netherlands Trial Registry: Care for
Work (NTR2886), Health and Motion (NTR3111), Guidance to Excel in Return to Work (NTR3151), Care for
Companies/Second Care (NTR3136).
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Background
Work disability
Many recent studies have focused on reduced productiv-
ity and work absence due to work disability in Western
countries [1-5]. Work disability prevents or detracts the
employee’s productivity and has many economic and
public health consequences, such as problems for
employers, employees, their families, and society [6-8].
In Western countries its main consequences are finan-
cial, due to reduced productivity, increased job turnover
and the cost of additional rehabilitation programs
[9-11]. In order to estimate the costs of work disability,
staff absence and presence needs to be recorded. Absen-
teeism refers to the total days lost from work. Presentee-
ism refers to attending work whilst still stick or disabled,
causing reduced productivity while at work [12]. Absen-
teeism and presenteeism can be used as integrated mea-
sures of physical, psychological and social functioning in
studies of working populations [12,13]. In the Nether-
lands, the Sickness Absence Reduction Act was intro-
duced in 1994 in an attempt to reduce absenteeism.
Although there has been a major reduction in absentee-
ism, nearly 3 million Dutch workers still suffer from one
or more chronic conditions which constrains their work
performance [14]. Sickness absence remains a large pro-
blem in terms of costs, labour participation and social
consequences [11,15,16]. The most common causes of
sickness absence are: musculoskeletal complaints, men-
tal health problems, and cardiovascular diseases [17,18].
Chronic diseases are more common among workers of
45 years and older, and it is expected that this age
group will greatly increase, leading to a growing number
of occupational health problems [17,18]. In the Nether-
lands, the total annual costs of absenteeism arising from
health complaints and work disability amounted to 26
billion Euros, which accounts for almost 5% of the gross
national product [14]. Additionally, Kremer and Steen-
beek (2010) have computed that approximately 21.5% of
absenteeism from work could be avoided if health ser-
vices and employer and employee opportunities
improved. To do this, shorter referral times, swifter
medical care, improved collaboration between health
care providers, reduced workload and an improved
work-life balance are important factors [17,18].
Return-to-work
Different return-to-work (RTW) interventions have been
developed and evaluated to reduce sickness absence due
to work disability. The effect, and occasionally the cost-
effectiveness, of RTW interventions have been demon-
strated in several observational studies [19-24], rando-
mized controlled trials [25-30] and reviews [31,32]. For
example, Franche et al. [31] concluded that work-based
RTW interventions among employees with work-disabil-
ity caused by musculoskeletal or other pain-related con-
ditions can reduce work disability duration and
associated costs. Lambeek et al. [33] showed that an
integrated care programme for work-disabled partici-
pants with chronic low back pain has the potential to
significantly reduce societal costs and improve care
effectiveness, quality of life and function on a broad
scale [33]. Other studies demonstrate that implementing
preventive interventions before sickness absence occurs
can be successful in preventing long-term sickness
absence [19,29,34,35]. Whilst these results are very pro-
mising for society, participants, and employers, more
research is necessary to confirm the long-term effects
and cost-effectiveness of such interventions. However,
methodological limitations in the current literature
make it difficult to assess the feasibility of the different
interventions proposed. These limitations include
restriction of the population of interest due to the strict
inclusion criteria, restrictions in the nature of the inter-
vention evaluated, restrictions in study-design and the
measurement of outcomes. There is moreover, a lack on
transparency and consensus about how to conduct trial-
based economic evaluations within the general field of
employability.
Objectives
This paper is the first of its kind to describe a transpar-
ent, uniform methodological design for the economic
evaluation of several different trial-based interventions
in the field of employability, disability and return-to-
work. Known as the ‘CASE-study’ (Cost-effectiveness
Analysis of Sustainable Employability), the project’s aim
is to evaluate at least five different employability inter-
ventions. All of the interventions share the common
aim of reducing absenteeism and optimising the
employability of employees with a known disability or
those at risk of disability due to musculoskeletal com-
plaints, mental health problems or a combination of
both musculoskeletal and mental health complaints. In
contrast with previous studies, the project design has no
population restrictions and allows for the economic eva-
luation of any employability intervention regardless of
the population they were developed for. Furthermore,
the project also includes interventions provided in the
primary and specialist health sectors as well as those
delivered within the workplace. It also includes interven-
tions aimed at reducing health care costs, wage replace-
ment costs and other intervention costs in addition to
improvements in return to disability duration and work
return rates as measured by self-reported return to work
dates, total duration of absence and subsequent recur-
rences, etc. Other outcomes include quality of life,
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quality of work life and general health status, etc. In
addition, we cast a wide net to include a range of study
designs since RCTs are not always possible in the eco-
nomic evaluation of employability interventions. This
paper describes the patient inflow in the event of an
RCT or a quasi-experiment with a matched controlled
design being conducted. For every employability inter-
vention, an effect study will be conducted. In addition,
from a societal perspective, a trial-based economic eva-
luation for every employability intervention will be car-
ried out in a consistent manner. The results of these
analyses will be discussed elsewhere in the future, but
we hypothesize that the employability intervention is
preferable in terms of costs, effects and utility compared
to usual care. This paper will therefore demonstrate the
strength of the CASE-study project in prescribing a
methodological design which allows for the assessment




Organisation of the CASE-study
We will carry out an economic evaluation designed for
at least five Dutch employability interventions. Those
undertaking the evaluation are not connected with the
organisations or individuals who have developed, or are
in the process of developing the employability interven-
tions so no competing interests arise. Within the CASE-
study each existing or innovative intervention will be
compared with usual care for work-disabled employees
or those at risk of work disability due to medical restric-
tions. At the start of the CASE-study, nine programmes
were interested in participating in the project. Unfortu-
nately four programmes could not collaborate because
they were unable to provide the minimum required
number of participants eligible for the study, or could
not provide a comparable control group. The remaining
five employability interventions have the ability to com-
ply to the minimal requirements and focus on primary
care, secondary or specialist care, and/or on the interac-
tion between the employer and employee. Two existing
employability interventions (called ‘Best Practices’) and
three newly developed employability interventions are
included in the study. The employability intervention
focussing on primary care aims to acknowledge the
importance of employability in general practice. This
intervention is under development at the University of
Nijmegen (UMC St Radboud). The employability inter-
vention in specialist care is being developed jointly by
the VU University Medical Centre Amsterdam (VUMC)
and the Institute for Health and Care Research (EMGO
+) and focuses on employability among patients who
suffer from rheumatoid arthritis. The third newly
developed intervention aims at improving the interac-
tion between the employee and his/her employer by
appointing an independent mediator. The intervention
is being developed by a separate team at Maastricht
University. One of the ‘Best Practice’ interventions,
developed by Health & Motion Nederland, offers
patients with physical health complaints the ability to
implement a range of exercises learned at the phy-
siotherapeutic setting in their working environment by
means of a workplace-intervention. The fifth and final
intervention is developed by Second Care/Care for
Companies (Best Practice) and aims at achieving sus-
tainable employability among patients with physical
and/or psychological health complaints using a multidis-
ciplinary approach. An overview of these interventions
is provided in Figure 1.
It is beyond the scope of this design article to describe
the precise content of each employability intervention in
detail. This will be done when the results of the eco-
nomic evaluation per employability intervention are
published. What is of importance in this paper is that
the employability interventions use an innovative, sys-
tematic approach in order to support work participation
in employees with health complaints. These are innova-
tive because both the healthcare system and the private/
work life of the employees are considered in the inter-
vention. The features of the interventions differ accord-
ing to the patient population, but the aim remains the
same: to reduce sickness absence and increase the
potential of achieving sustainable employability.
The protocol for this study has been approved by the
Ethics Committee of Psychology (ECP107) at Maastricht
University, the Netherlands.
Usual work resumption care in the Netherlands
The Gatekeeper Improvement Act stipulates that the
responsibility for work resumption lies with the
employer and the employee. The employer is obliged to
start an employee’s work resumption programme as
quickly as possible, so the employee can resume his/her
own work or other adequate work. In return, the
employee should accept the work activities the employer
provides. Furthermore, and unique in the world, the
Dutch reintegration process provides the employer with
salary and mandatory reintegration obligations for a per-
iod of two years [36]. Participants included in the care
as usual group will continue to receive care for their
health complaints, but attention to work-related factors
influencing these will only occur minimally. Neverthe-
less, since attention to labour and health-related charac-
teristics is obligatory under the Gatekeeper
Improvement Act [36], participants in the care as usual
group who are work-disabled will also receive adequate
care (care as usual). Participants included in the control
group will be treated and supervised according to good
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clinical practice based on the evidence-based guidelines
of the Dutch association of occupational physicians
[37,38].
Participants
Employees eligible for participation in the study will be
work-disabled or at risk of work disability due to medi-
cal restrictions. In order to identify these employees, we
will use employer registration forms, registrations with
health care organizations and insurance companies, and
registration forms from those providing the intervention.
Employees eligible for inclusion will be 18 to 63 years of
age, perform paid labour for at least 12 h per week, and
are able to communicate in Dutch. Reasons for exclu-
sion are absenteeism for 1.5 years or longer, fulltime
students with a student job, informal caregivers and/or
volunteers.
In order to recruit a sufficient number of eligible
employees, one or more health care providers providing
an employability intervention will screen service users
for inclusion in the study. When appropriate, informa-
tion on the research will be provided to the patient.
This will be done orally by the health care provider,
possibly supported by a handout containing contact
information for the researchers, what is expected of par-
ticipants, privacy concerns, and so on. A self-completion
card will be attached to each flyer (handout) consisting
of a short checklist for inclusion and informed consent
form for signing. The employee is requested to fill in
the short checklist, sign the informed consent form, and
send these back to the researcher. Participants will have
at least 1 week to consider their participation in the
study before signing the informed consent form. Partici-
pants will be screened for exclusion by the researcher
on the basis of answers provided on the checklist. If an
employee meets all the selection criteria and is willing
to sign the consent form, randomization or matching
will then place. Before the intervention starts, the first
(baseline) measurement occurs. An email with a login
code is sent to all participants, and they will be asked to
fill in the baseline questionnaire. The questionnaire for
the intervention group is identical to the one for the
control group.
Study design
As suggested by Drummond et al. (2001), a randomized
controlled trial (RCT) remains the standard design for
evaluating the relative effect of candidate interventions
[39]. However, due to practical reasons, randomly asses-
sing participants to the employability intervention or
care as usual is not always possible in the CASE-study.
Employers and occupational physicians are legally
obliged to offer sickness absence guidance, and to do so,
they refer employees to one or more employability inter-
ventions. Thus, a quasi experiment, comparing employ-
ees who are allocated to an experimental intervention in
Figure 1 Employability interventions included in the CASE-study.
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a non-random manner with those non-randomly
assigned to a conventional intervention is regarded as
the next best study design. Unlike an RCT, a quasi
experiment consists of a control group derived from a
large non-equivalent population. The variables are not
manipulated, and participants are selected on the basis
of matched criteria with those in the non-intervention
group. Randomisation is not used therefore, and partici-
pants/control members are selected on the basis of their
having an equal chance of demonstrating a causal rela-
tionship between the intervention and its outcomes for
the control or experimental intervention. Both quasi
experiments and RCTs are acceptable for the economic
evaluation of employability interventions. The antici-
pated flow of subject enrolment in a quasi experiment
or RCT is shown graphically in Figure 2.
Randomization/matching
In the case of randomization, the minimization method
will be applied. Minimization aims to ensure an excel-
lent balance for several prognostic factors in small
groups [40]. Employees consenting to participate will be
pre-stratified according to age (18-32 years, 33-48 years,
49-64 years), gender, and working hours (12-24 h/week,
> 24 h/week). Since health care providers will treat par-
ticipants in both the intervention and in the control
groups, the study cannot be blinded. Matching i.e. for-
mulating experimental and control groups on the basis
of pairing participants on the basis of predetermined
matching criteria will be used. These matched-criteria
are age, working hours and health complaints. Thus, an
employee in the intervention group will be matched to
someone meeting the same criteria who will then act as
a member of the control group.
Timeline of the study
During recruitment, employees will be asked whether
they want to participate in the research by one or more
health care providers operating in the employability
intervention. Participation requires employees to fill in a
self-reported online questionnaire at time points T0
(baseline), T1 (6 months after admission), FU1 (12
month follow-up) and FU2 (18 month follow-up). After
18 months the study results for sustainable employabil-
ity and quality of life are expected to extend into subse-
quent years. The timeline of the study can also be found
in Figure 2.
Outcome assessment and data collection
The outcome assessment and data collection is identical
for every employability intervention. Questions derived
from different questionnaires, such as the ‘National
Working Conditions Survey’ (NEA) [18], ‘EuroQol 5
Dimensions 5 Levels’ (EQ-5D-5 L) [41], ‘Short Form
Health Survey’ (SF-36) [42], ‘Trimbos/iMTA question-
naire for costs associated with psychiatric illness’ (TIC-
P) [43], and ‘the productivity and disease questionnaire’
(PRODISQ) [44], are combined into a retrospective self-
reported questionnaire. The economic evaluation will be
analysed from a societal perspective. This means that
the most appropriate set of costs captured from the data
(e.g. health care costs, productivity costs etc.), regardless
of where the costs or benefits occur, will be applied [36].
Effect evaluation
Primary outcome measure
The primary outcome measure in the CASE-study is
reduced sickness absence duration in calendar days.
Reduced sickness absence will be measured subjectively
via patient self-report records. The duration of sick
leave will be calculated as the time in calendar days
since reduced productivity occurred (baseline). This will
then be compared with the productivity time of a per-
son at 6, 12, and 18 months. The success of an interven-
tion will be defined by comparing the average reduction
in sickness absence between the intervention group and
the control group. The employability intervention is
effective when the employees in the intervention group
return to work twice as quickly as employees in the con-
trol group. Data on sickness absence duration will be
gathered by using the productivity and disease question-
naire (PRODISQ) [45].
Secondary outcome measures
Data on secondary outcome measures will be gathered
by means of self-administered questionnaires such as,
NEA [18], EQ-5D-5 L [41], SF-36[42], TIC-P [43] and
PRODISQ[44].
- Sustainable employability After commencing a treat-
ment intervention, a follow-up measurement will take
place at 12 and 18 months to analyze the sustainability
of employability. An intervention will be deemed to be
unsuccessful when absenteeism of more than fourteen
consecutive days after receiving the productivity inter-
vention occurs. On the basis of previous research, it will
be assumed that the long-term effect of the employabil-
ity intervention stabilizes after 18 months [24].
- Self-rated health Self-related health will be assessed
using one item from the Short Form Health Survey (SF-
36). This widely used measurement tool describes how a
respondent values and assess his/her general health [46].
Data gathered via questions derived from the NEA [18]
will be used to detect health complaints underlying
work disability and co-morbidity.
- Quality of Life An explorative analysis of productivity
costs and quality of life showed a clear relationship
between both variables [46]. Therefore, quality of life
will be measured in work-disabled employees by using
the EuroQoL five dimensions, five levels (EQ-5D-5 L)
[41]. The EQ-5D-5 L comprises 5 dimensions: mobility,
self-care, usual activities, pain/discomfort and anxiety/
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depression. There are five possible answers for each
dimension, defining (55) 3125 possible health states.
Furthermore, the EQ-5D-5 L includes a visual analogue
scale (VAS) rating from zero (worst imaginable health
state) to 100 (best imaginable health state) [41].
Economic evaluation
Self-reported questionnaires will capture the costs and
benefits from a societal perspective, thus independently
of those who bear the costs, and those who receive the
benefits. Self-reported questionnaires appear to be a
Figure 2 Participants flow.
Noben et al. BMC Public Health 2012, 12:43
http://www.biomedcentral.com/1471-2458/12/43
Page 6 of 10
reliable alternative for cost-diaries, at least for a recall
period of 6 months, since participants will still remem-
ber significant life events [45,47-49]. Costs that arise in
different years will be discounted at 4% [50]. Costs
directly related to the provision of the employability
intervention will be objectively registered via the provi-
ders of the employability intervention. Direct healthcare
costs and direct non-healthcare costs comprise respec-
tively: costs of visits for primary and secondary care,
home care, drugs, and for visits to an alternative or
informal health therapist. Direct costs will be measured
by an adapted version of the Trimbos/iMTA question-
naire for costs associated with psychiatric illness [43]
and will be estimated on the basis of prices suggested in
the cost calculation guidelines for healthcare in the
Netherlands [50]. The prices of prescribed drugs will be
based on Daily Defined Dosage (DDD) taken from the
Royal Dutch Society for Pharmacy [50]. Indirect costs
will be determined by measuring data on the costs of
lost productivity due to work disability and are derived
through the PRODISQ [46]. The indirect costs of pro-
duction loss due to sick leave will be calculated by
means of the friction cost method whereby the number
of days of sickness absence and lost earnings are used to
calculate the costs of production losses. Lost earnings
will be determined on the basis of the differences
between income at baseline and income at follow-up.
Based on a mean added value of the Dutch working
population, production losses are confined to the period
needed to replace a sick employee [44]. The indirect
costs of productivity losses without sick leave will be
based on the number of days in which productivity was
hindered due to health complaints and an estimation of
the efficiency in these days [51]. Furthermore, compen-
sation will be taken into account when determining pro-
duction loss. Information about the number of hours to
catch up with the work will be obtained as well as the
way in which this compensation was achieved. If these
data are considered invalid, for example because the
income data of too many employees are unknown, we
will use national data of average production value per
worker, related to the education level and labour sector.
Sample size
For the economic evaluation of the three newly devel-
oped employability interventions, the study sample size
was pre-specified by the researchers and the developers
of the particular interventions. For the sample size cal-
culation of the existing ‘Best Practices’, we expect that a
Hazard Ratio (HR) of 2.0 indicates a relevant difference
in the average number of hours/days of lost work due to
work disability between employees in the intervention
group and employees in the control group after 18
months. This HR is based on findings of recent studies
in occupational health care [25,52-55]. With a power of
80% at a 0.05 significance level, the sample size was cal-
culated to be 120 employees [56]. Taking into account a
dropout rate of 15%, 5% per follow-up measurement
time, a total of 142 participants are needed. A dropout
is defined as an employee who has not filled in the
questionnaire at one or more measurement time-points.
Data analyses
Effectiveness
All statistical analyses, performed to distinguish differ-
ences between the control group and the intervention
group, will be performed according to the intention-to-
treat principle. This means that the participants will
remain in the group they were allocated to at baseline.
All data regarding primary and secondary outcomes will
be analysed using descriptive statistics. To control for
protocol deviations likely to cause bias, data will be ana-
lyzed using per-protocol analyses whereby outcomes will
be compared between those participants who received at
least one or a partial intervention session and the con-
trol group. With the aim of correcting for possible
regression to the mean, the baseline value of the parti-
cular outcome variable will be added to the model. Days
of sick leave in the year before the inclusion, measured
at baseline, will be added as a potential effect-modifier.
Diagnosis and prognostic parameters can be confoun-
ders, thus the Cox regression analysis for confounders
will be used to adjust for differences between control
and intervention groups. If necessary, differences in
baseline will be adjusted for prognostic dissimilarities.
Missing data will be handled using SPSS missing value
analysis on item level. Completely missing measure-
ments will be handled using multiple imputation.
The primary dependent variable is days of absence
from work. In order to estimate the number of absence
days, survival analyses will be used. There are two rea-
sons why we opted to use survival statistics. Firstly, the
time to sustainable employability is unlikely to be nor-
mally distributed which will make parametric statistical
analysis difficult or inappropriate. Increasing productiv-
ity can occur quite early, possibly within months, but
can also, as expected in the care as usual situation, may
not be prolonged or may even decrease again. Secondly,
survival analysis accounts for dropout by the technique
of censoring. Participants who drop out will have the
same hazard of sustainable employment than those that
remained in the study. The Cox Proportional hazard
model will therefore be used to analyse the HR of the
days of sick leave duration. Reduced sickness absence
duration in calendar days will be analysed with the
Kaplan Meier survival method, and the differences in
absence duration between both groups will be tested
with a log rank test.
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To analyse the secondary outcomes, longitudinal mul-
tilevel analyses will be used to assess the differences in
health and quality of life between the control group and
the intervention group.
Data will be analysed in SPSS 17.0.
Economic evaluation
The economic evaluation will be carried out according
to the intention-to-treat principle. Non-parametric boot-
strapping (1000 replications) will be used to obtain 95%
confidence intervals to estimate the uncertainty sur-
rounding the cost differences, because cost-data are
usually skewed to the right [57].
For the cost-effectiveness analysis, the incremental
cost-effectiveness ratio (ICER) will be calculated by
assessing the ratio of the differences in costs between
the groups to the differences in effects between the
groups. The ICER indicates whether the additional
investments needed for the interventions gain at least
one extra unit of effect compared with care as usual
[57]. The cost-utility ratio will be calculated by the
incremental costs divided by the difference in QALYs
[39,58].
Bootstrapping with 5000 replications will be used to
estimate the sample-uncertainty around the point esti-
mates (ICER and ICUR). The bootstrapped ICERs and
ICURs will be graphically presented on a cost-effective-
ness plane. Furthermore, acceptability curves will show
the probability that the employability intervention is
cost-effective at a specific ceiling ratio, which is the maxi-
mum amount of money society is willing to pay to gain
one extra unit of effect or a gain in quality of life [59].
Finally, the robustness of the different parameters on the
cost-effectiveness calculation will be assessed by sensitiv-
ity analyses. Data processing will be done in SPSS 17.0
and bootstrapping will be carried out in Excel.
Discussion
This study protocol provides detailed information on
how to assess the effectiveness and cost-effectiveness of
employability interventions among employees with work
disabilities or employees at risk of becoming work-dis-
abled due to health complaints. The results derived
from these economic evaluations can benefit the indivi-
dual employee, the employer and the broader occupa-
tional health practice sector because illness duration,
care consumption and costs of lost productivity are
expected to decrease if the employability intervention is
cost-effective. For society as a whole, cost-effective
employability interventions are attractive since they are
expected to increase labour participation and public
health. Furthermore, we feel that productivity is the key
to higher economic growth as we are facing an ageing
population.
A limitation of this study-design is the generalisability
to other countries. The employability interventions are
specifically tailored for the Dutch context in which they
will be implemented. When applying these interventions
in other countries, specific characteristics of the popula-
tion in relation to the societal, political and cultural
context in which the interventions are to be used should
be taken into account. Although international generali-
sability might be restricted and require adaptation to the
intervention, lessons can be learned and implementation
advice given to those engaging in future work.
Selection bias cannot be ruled out in this design
because we ask the healthcare provider to select
employees to participate in our study. As a consequence,
healthcare providers cannot be blinded. Furthermore,
the consultation with the health care provider might
change the participants’ point of view on work disability.
This ‘Hawthorne effect’ will be born in mind and might
overestimate or underestimate the effect of the interven-
tion. However, we feel that minor interactions such as
the provision of information about the study will not be
an important source of bias.
The strengths of this pragmatic design looking at the
cost-effectiveness of employability interventions versus
usual care, is the comparison under ‘real life’ circum-
stances of the intervention and control variables.
Resource use is self-reported by participants and will be
collected separately from the unit costs or prices of
those resources. We will keep in mind the possibility
that health care and intervention providers in different
settings may wish to apply their own prices to the units
of resource use. Furthermore, due to the standard recall
period of 6 months, an adequate estimation of resource
use is linear over time. This linear time trend restricts
overestimation and underestimation of resource use
between two consecutive measurement moments. An
additional strength of this design is the inclusion of
losses due to sick leave and the costs of using health
care facilities together with productivity losses during
working periods whilst unwell (presenteeism). In devel-
oping the methodology, we kept in mind the possibility
that the employability and usual care interventions may
have different effects on the component of reduced pro-
ductivity while at work and therefore capture these.
Besides internal validity, external validity of the results
of the economic evaluation is reached by analysing the
data from a societal perspective. We can split the calcu-
lated cost-effectiveness from the societal perspective to
other perspectives, e.g. employee perspective, organisa-
tional perspective, etc.
To conclude, the research design provided in this arti-
cle will be applied to each employability intervention
included in the CASE-study. The CASE-study is the first
study assessing the cost-effectiveness of different
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employability interventions. In addition, this design
might contribute to new and better guidelines in the
conduction of future economic evaluations in the occu-
pational health sector. The results of the CASE-study
will become available between 2012 and 2014.
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